NovoCure Future Growth
Future criteria checks 1/6
NovoCure is forecast to grow earnings and revenue by 3.2% and 8.1% per annum respectively. EPS is expected to grow by 6.4% per annum. Return on equity is forecast to be -218.9% in 3 years.
Key information
2.1%
Earnings growth rate
6.4%
EPS growth rate
Medical Equipment earnings growth | 18.3% |
Revenue growth rate | 9.8% |
Future return on equity | -420.1% |
Analyst coverage | Good |
Last updated | 02 May 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 656 | -198 | -165 | N/A | 6 |
12/31/2025 | 581 | -203 | -125 | -143 | 7 |
12/31/2024 | 538 | -189 | -136 | -143 | 7 |
12/31/2023 | 509 | -207 | -100 | -73 | N/A |
9/30/2023 | 504 | -197 | -89 | -62 | N/A |
6/30/2023 | 508 | -174 | -46 | -21 | N/A |
3/31/2023 | 522 | -141 | -5 | 18 | N/A |
12/31/2022 | 538 | -93 | 9 | 31 | N/A |
9/30/2022 | 543 | -82 | 20 | 49 | N/A |
6/30/2022 | 545 | -68 | 24 | 51 | N/A |
3/31/2022 | 538 | -59 | 36 | 61 | N/A |
12/31/2021 | 535 | -58 | 59 | 83 | N/A |
9/30/2021 | 546 | -27 | 106 | 122 | N/A |
6/30/2021 | 545 | -5 | 113 | 128 | N/A |
3/31/2021 | 527 | 12 | 99 | 115 | N/A |
12/31/2020 | 494 | 20 | 84 | 99 | N/A |
9/30/2020 | 450 | 19 | 40 | 53 | N/A |
6/30/2020 | 409 | 12 | 24 | 37 | N/A |
3/31/2020 | 380 | 9 | 22 | 33 | N/A |
12/31/2019 | 351 | -7 | 16 | 27 | N/A |
9/30/2019 | 322 | -27 | 27 | 36 | N/A |
6/30/2019 | 294 | -41 | 19 | 27 | N/A |
3/31/2019 | 269 | -55 | 4 | 11 | N/A |
12/31/2018 | 248 | -64 | -9 | -2 | N/A |
9/30/2018 | 232 | -59 | -28 | -22 | N/A |
6/30/2018 | 217 | -59 | -32 | -25 | N/A |
3/31/2018 | 194 | -64 | -30 | -23 | N/A |
12/31/2017 | 177 | -62 | -40 | -33 | N/A |
9/30/2017 | 154 | -73 | N/A | -44 | N/A |
6/30/2017 | 125 | -95 | N/A | -80 | N/A |
3/31/2017 | 105 | -114 | N/A | -104 | N/A |
12/31/2016 | 83 | -132 | N/A | -108 | N/A |
9/30/2016 | 65 | -143 | N/A | -120 | N/A |
6/30/2016 | 52 | -135 | N/A | -109 | N/A |
3/31/2016 | 41 | -124 | N/A | -102 | N/A |
12/31/2015 | 33 | -112 | N/A | -100 | N/A |
9/30/2015 | 25 | -102 | N/A | -91 | N/A |
6/30/2015 | 20 | -94 | N/A | -87 | N/A |
3/31/2015 | 18 | -86 | N/A | -83 | N/A |
12/31/2014 | 15 | -81 | N/A | -74 | N/A |
12/31/2013 | 10 | -77 | N/A | -53 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 038 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 038 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 038 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 038's revenue (8.1% per year) is forecast to grow faster than the German market (5.5% per year).
High Growth Revenue: 038's revenue (8.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 038 is forecast to be unprofitable in 3 years.